From: [redacted] <[redacted]>
Sent: 09 January 2014 10:22
To: TA Comm B
Subject: ACD - Multiple sclerosis (relapsing-remitting) - alemtuzumab [ID539]

Dear Sir/Madam

I am just writing to inform you that the Royal College of Pathologists has no comments to make on the ACD for the above technology appraisal.

Kind regards

[redacted]
The Royal College of Pathologists
2 Carlton House Terrace
London, SW1Y 5AF
Tel: [redacted]
Fax: [redacted]
Website: www.rcpath.org

This email and any files transmitted with it are confidential and are intended solely for the use of the individual(s) to whom they are addressed. If you have received this email in error please notify postmaster@rcpath.org and delete the material from your computer. The Royal College of Pathologists gives no warranty as to the accuracy or completeness of this email after it is sent over the Internet and accepts no responsibility for changes made after it is sent. Any opinion expressed in this email may be personal to the author and may not necessarily reflect the opinions of the College. We have taken precautions to minimise the risk of transmitting software viruses, but we advise that you carry out your own virus checks on any attachments to this message. We cannot accept liability for any loss or damage caused by software viruses. Please consider your impact to the environment before printing this email.

The Royal College of Pathologists is a registered charity - No: 261035.

Delivered via MessageLabs